Edwards Lifesciences Corp

Edwards Lifesciences Corporation develops and manufactures medical devices focused on structural heart disease. The company's business encompasses surgical and catheter-based therapies across three core product groups: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, and Surgical Structural Heart. Its portfolio features artificial tissue replacement valves, repair platforms, and annuloplasty rings designed to address valvular conditions affecting the aortic, mitral, tricuspid, and pulmonary heart valves. Edwards Lifesciences provides these technologies to healthcare providers, serving physicians, cardiac surgeons, interventional cardiologists, nurses, hospital systems, and procurement organizations.

The company operates globally, selling its heart valve systems and related medical devices across approximately 100 countries, including the United States, Japan, France, Germany, Italy, Spain, Canada, and the United Kingdom. It maintains manufacturing sites in the United States, Singapore, Costa Rica, and Ireland, alongside research facilities in the United States and Israel. Edwards Lifesciences maintains its principal executive offices in Irvine, California.

Summary of the business section of Edwards Lifesciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had approximately 16,000 employees worldwide, the majority of whom were located in the United States, Singapore, and Costa Rica.”